PR Newswire

Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD

Written by PR Newswire

SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) for treatment of Attention Deficit Hyperactivity...

Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD

HomeBuilder only makes sense as a nod to…

Big Breastfeeding: Best Positions and Su…

Tree Pruning Mistakes and Tips

Unleash Your Inner Gardener: Mastering T…

The government has just sold $15 billion…

The Bulletin Magazine

Why Commercial Scaffolding Services Are Critical for Large Scale Projects

Sydney Suburban Living: Combining Style, Security and Functionality

Professional Assistance to a successful Australian relocation

What is a vendor advocate?

Understanding The Benefits Of A Sleep Apnea Mask For Effective Therapy

The Importance Of A 24 Hour Emergency Electrician For Fast And Safe Electrical Response

The Importance Of Vehicle Protection With Bash Plates And Underbody Upgrades

How to Find the Best Off Road Caravans for Australian Adventures

How Rims And Tyres For Sale Sydney Improve Performance, Safety And Driving Confidence

How Huggies Nappies Support Comfort, Absorption And Protection For Babies Of All Ages

How Lighting Shop Perth Stores Help Homeowners Transform Their Spaces With Quality Lighting Solutions

Disability Home Care Services: Empowering Lives Through Quality In-Home Support